To date, most of the prostate cancer-specific experience targeting this pathway comes from studies testing allosteric mTOR inhibitors, with these studies all generally failing to demonstrate sufficient activity to warrant further study [111–115]. This evidence concerns the gene MTOR and Familial prostate cancer.